LYON, France, July 12 – An Aventis executive said Thursday it was too early to speculate about how the proposed sale of Aventis CropScience to Bayer would impact the company’s genomics efforts.

“I don’t know if there will be any effect; it’s too early to tell,” Georges Freyssinet, head of global genomic research at CropScience, told GenomeWeb.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.